Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations

Azacitidine is recommended for patients with higher-risk myelodysplastic syndromes (MDS) who are not eligible for intensive therapy or for patients with lower-risk MDS who have thrombocytopenia or neutropenia or have anemia that is unresponsive to other therapies. However, standard treatment with az...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yoo-Jin, Jang, Jun Ho, Kwak, Jae-Yong, Lee, Je-Hwan, Kim, Hyeoung-Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698413/
https://www.ncbi.nlm.nih.gov/pubmed/23826577
http://dx.doi.org/10.5045/br.2013.48.2.87

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698413/
https://www.ncbi.nlm.nih.gov/pubmed/23826577
http://dx.doi.org/10.5045/br.2013.48.2.87

Ejemplares similares